News Ipsen

Stocks

IPN

FR0010259150

Pharmaceuticals

Market Closed - Euronext Paris 18:55:00 08/10/2026 +03			After hours 22:59:59
141.50 ^EUR	-2.41%		142.10	+0.42%

10:59am	Tesco cashes in, OPmobility takes a hit
09-25	US FDA approves Mirum's drug for rare bone disorder	RE

All News

Mentions Relevance

09-28	IPSEN - Buy-back programme - Art 5 of MAR - Week 39 - 2026	GL
09-25	US FDA approves Mirum's drug for rare bone disorder	RE
09-22	IPSEN - Buy-back programme - Art 5 of MAR - Week 38 - 2026	GL
09-22	Europe Is Losing the Pharma Investment Race — But the Comeback Is Within Reach: An open letter from the Chairs of AstraZeneca, Boehringer Ingelheim, Chiesi Group, Ipsen, GSK, Novo, Novartis, Roche, and Sanofi	PU
09-21	Ipsen Shares Fall After Early Launch of U.S. Generic Rival	DJ
09-21	The arrival of a generic rival to Somatuline rattles Ipsen
09-18	Ipsen Announces Board and Committee Changes	CI
09-18	Ipsen appoints Mariette Finet to its Board of Directors	GL
09-18	AlphaValue/Baader Europe Ups Price Target, Forecasts for Ipsen on 'Solid' H1 Performance	MT
09-17	Ipsen: Incorporating solid H1 operational performance + guidance upgrade
09-17	Ipsen extends its pullback despite AlphaValue
09-15	IPSEN - Buy-back programme - Art 5 of MAR - Week 36- 2026	AQ
09-14	IPSEN - Buy-back programme - Art 5 of MAR - Week 37 - 2026	GL
09-12	Health Care Flat as Traders Rotate Back Into Fuel-Sensitive Sectors - Health Care Roundup	DJ
09-07	IPSEN - Buy-back programme - Art 5 of MAR - Week 36- 2026	GL
08-31	IPSEN - Buy-back programme - Art 5 of MAR - Week 35 - 2026	GL
08-24	IPSEN - Buy-back programme - Art 5 of MAR - Week 34 - 2026	GL
08-21	Ipsen S.A. completed the acquisition of Kartos Therapeutics, Inc.	CI
08-21	Ipsen Wraps Up Purchase of US-based Kartos Therapeutics	MT
08-21	Ipsen closes the acquisition of Kartos Therapeutics
08-21	Ipsen completes acquisition of Kartos Therapeutics, strengthening late-stage Oncology pipeline	GL
08-17	IPSEN - Buy-back programme - Art 5 of MAR - Week 33 - 2026	GL
08-17	Kepler Cheuvreux Boosts Ipsen PT, Maintains Hold Rating	MT
08-10	IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2026	GL
08-04	Marengo Therapeutics, Inc. and Ipsen S.A. Nominate First Drug Candidate Under Strategic Tristar Collaboration	CI